Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Samnick, S.
Right arrow Articles by Kirsch, C.-M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Samnick, S.
Right arrow Articles by Kirsch, C.-M.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
Journal of Clinical Oncology, Vol 20, Issue 2 (January), 2002: 396-404
© 2002 American Society for Clinical Oncology

Clinical Value of Iodine-123-Alpha-Methyl-L-Tyrosine Single-Photon Emission Tomography in the Differential Diagnosis of Recurrent Brain Tumor in Patients Pretreated for Glioma at Follow-Up

By Samuel Samnick, Jochen B. Bader, Dirk Hellwig, Jean Richard Moringlane, Christof Alexander, Bernd F.M. Romeike, Wolfgang Feiden, Carl-Martin Kirsch

From the Departments of Nuclear Medicine, Neurosurgery, and Neuropathology, Saarland University Medical Center, Homburg/Saar, Germany.

Address reprint requests to Samuel Samnick, PhD, Department of Nuclear Medicine, Saarland University Medical Center, D-66421 Homburg/Saar-Germany; email: rassam{at}med-rz.uni-saarland.de

PURPOSE: To assess the clinical potential of iodine-123-alpha-methyl-L-tyrosine (IMT) and single-photon emission tomography (SPET) in the differential diagnosis of recurrences in patients pretreated for gliomas at follow-up.

PATIENTS AND METHODS: Seventy-eight patients were examined after primary therapy over 36 months. Histopathologic diagnoses of all patients was known at first treatment; magnetic resonance and/or computed tomography examination was performed in addition to IMT-SPET. Cerebral SPET images were acquired 20 minutes after intravenous application of 190 ± 10 MBq of IMT. SPET images were classified as positive or negative for recurrent tumor visually and by calculating the ratios between tracer accumulation in the lesion and the unaffected contralateral regions of reference using region of interest. Final diagnoses were based on prospective clinicopathologic findings obtained independently of IMT-SPET.

RESULTS: IMT-SPET detected all high-grade recurrent gliomas (grade 4; sensitivity, 100%). A difference could be demonstrated in grade 2 and 3 recurrences (sensitivity, 84% and 92%, respectively). Moreover, benign posttherapeutic lesions (postoperative scars, radiation necrosis) were correctly diagnosed as negative for tumor recurrence. In general, IMT uptake in grade 2 (1.45 ± 0.24) was significantly lower than that in grades 3 (1.70 ± 0.41) and 4 (1.88 ± 0.32). However, it was difficult to evaluate tumor grade only from the IMT accumulation in individual cases.

CONCLUSION: IMT-SPET seems highly useful for detecting and delineating recurrent gliomas and differentiating between benign posttherapeutic lesions and malignant tumor tissue. It may be a valuable clinical tool to diagnose recurrences in patients pretreated for gliomas at follow-up. However, it showed limitations in determining histologic tumor grade.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
JNMHome page
S. Samnick, B. F. Romeike, T. Lehmann, I. Israel, C. Rube, A. Mautes, C. Reiners, and C.-M. Kirsch
Efficacy of Systemic Radionuclide Therapy with p-131I-Iodo-L-Phenylalanine Combined with External Beam Photon Irradiation in Treating Malignant Gliomas
J. Nucl. Med., December 1, 2009; 50(12): 2025 - 2032.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
C. Plathow and W. A. Weber
Tumor Cell Metabolism Imaging
J. Nucl. Med., June 1, 2008; 49(Suppl_2): 43S - 63S.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Neuroradiol.Home page
P. A. Hein, C. J. Eskey, J. F. Dunn, and E. B. Hug
Diffusion-Weighted Imaging in the Follow-up of Treated High-Grade Gliomas: Tumor Recurrence versus Radiation Injury
AJNR Am. J. Neuroradiol., February 1, 2004; 25(2): 201 - 209.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
J. Knisely
Conformal Radiotherapy for High-Grade Gliomas: How Much Is Too Much?
J. Clin. Oncol., August 1, 2002; 20(15): 3357 - 3358.
[Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2002 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online